CytomX Therapeutics, Inc. CTMX
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is an oncology drug developer. Its lead program, Varsetatug masetecan (Varseta-M, CTMX-2051), is in Phase 1 for EpCAM-expressing solid tumors; late-line metastatic colorectal cancer. Its next catalyst on record is Varseta-M + chemo combination: Phase 1/2 study start (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Varseta-M + chemo combination — Phase 1/2 study start (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Varseta-M + bevacizumab/5-FU/leucovorin | 2nd line mCRC | antibody | Phase 2 |
| Varseta-M monotherapy (EpCAM ADC) | Late-line metastatic CRC (Phase 1 expansion / dose optimization) | antibody | Phase 1 |
| Varseta-M + bevacizumab | Metastatic CRC | antibody | Phase 1 |
| Varseta-M expansion cohorts | Gastric/GEJ, EpCAM-selected PDAC, EpCAM-selected biliary tract cancer | antibody | Phase 1 |
| CX-801 (masked IFNa2b) | Advanced melanoma (monotherapy and with pembrolizumab) | protein/peptide | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.